ATHS
MCID: ATH013
MIFTS: 63

Atherosclerosis Susceptibility (ATHS)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Atherosclerosis Susceptibility

MalaCards integrated aliases for Atherosclerosis Susceptibility:

Name: Atherosclerosis Susceptibility 57
Atherosclerosis 57 12 73 36 29 54 42 44 15 62 17 70 32
Atherosclerosis, Susceptibility to 57 13 6
Atherogenic Lipoprotein Phenotype; Alp 57
Atherogenic Lipoprotein Phenotype 57
Arteriosclerosis 70
Aths 57
Alp 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant
? same as ldlr


HPO:

31
atherosclerosis susceptibility:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:1936
OMIM® 57 108725
KEGG 36 H02505
ICD9CM 34 440
MeSH 44 D050197
NCIt 50 C35768
SNOMED-CT 67 155414001
ICD10 32 I70
MedGen 41 C1531719
SNOMED-CT via HPO 68 190785000 22298006 263681008
UMLS 70 C0003850 C0004153

Summaries for Atherosclerosis Susceptibility

MedlinePlus : 42 Atherosclerosis is a disease in which plaque builds up inside your arteries. Plaque is a sticky substance made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. That limits the flow of oxygen-rich blood to your body. Atherosclerosis can lead to serious problems, including Coronary artery disease. These arteries supply blood to your heart. When they are blocked, you can suffer angina or a heart attack. Carotid artery disease. These arteries supply blood to your brain. When they are blocked you can suffer a stroke. Peripheral arterial disease. These arteries are in your arms, legs and pelvis. When they are blocked, you can suffer from numbness, pain and sometimes infections. Atherosclerosis usually doesn't cause symptoms until it severely narrows or totally blocks an artery. Many people don't know they have it until they have a medical emergency. A physical exam, imaging, and other diagnostic tests can tell if you have it. Medicines can slow the progress of plaque buildup. Your doctor may also recommend procedures such as angioplasty to open the arteries, or surgery on the coronary or carotid arteries. Lifestyle changes can also help. These include following a healthy diet, getting regular exercise, maintaining a healthy weight, quitting smoking, and managing stress. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Atherosclerosis Susceptibility, also known as atherosclerosis, is related to cerebral atherosclerosis and generalized atherosclerosis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atherosclerosis Susceptibility is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Lipid and atherosclerosis and Toll-like Receptor Signaling Pathway. The drugs Everolimus and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotypes are hypertriglyceridemia and myocardial infarction

OMIM® : 57 The atherogenic lipoprotein phenotype (ALP) is a common heritable trait characterized by a preponderance of small, dense low density lipoprotein (LDL) particles (subclass pattern B), increased levels of triglyceride-rich lipoproteins, reduction in high density lipoprotein, and a 3-fold increased risk of myocardial infarction (summary by Nishina et al., 1992). The so-called atherogenic lipoprotein phenotype was shown by Austin et al. (1988) to be independently associated with an increased risk for coronary artery disease. Allayee et al. (1998) concluded, furthermore, that there is a genetically based association between familial combined hyperlipidemia (FCHL; 144250) and small, dense LDL particles and that the genetic determinants for LDL particle size are shared, at least in part, among FCHL families and the more general population at risk for coronary artery disease. Juo et al. (1998) concluded from a bivariate segregation analysis of small, dense LDL particles and elevated apolipoprotein B levels (APOB; 107730), which are commonly found together in members of FCHL families, that the 2 traits share a common major gene plus individual polygenic components. The common major gene was estimated to explain 37% of the variance of adjusted LDL particle size and 23% of the variance of adjusted apoB levels. (108725) (Updated 05-Apr-2021)

KEGG : 36 Atherosclerosis is a chronic inflammatory disease marked by a narrowing of the arteries from lipid-rich plaques present within the walls of arterial blood vessels. It represents the root cause of the majority of cardiovascular diseases (CVDs) and their complications, including conditions such as coronary artery disease, myocardial infarction and stroke. Atherosclerosis develops as a result of the interactions of various genetic and environmental factors. Elevated cholesterol and LDLcholesterol (LDL-C) levels are the main risk factors that associated with the formation of atherosclerotic plaques and the development of atherosclerosis.

PubMed Health : 62 About atherosclerosis: Atherosclerosis (ath-er-o-skler-O-sis) is a disease in which plaque (plak) builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. Atherosclerosis can lead to serious problems, including heart attack, stroke, or even death.

Wikipedia : 73 Atherosclerosis is a disease in which the wall of the artery develops abnormalities, called lesions.... more...

Related Diseases for Atherosclerosis Susceptibility

Diseases related to Atherosclerosis Susceptibility via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1128)
# Related Disease Score Top Affiliating Genes
1 cerebral atherosclerosis 33.2 CRP APOE APOB APOA1
2 generalized atherosclerosis 32.8 INS CRP APOE APOB
3 hepatic lipase deficiency 32.6 APOE APOA1
4 carotid stenosis 32.5 VCAM1 CRP CDKN2B-AS1 APOE
5 carotid artery disease 32.4 PON1 CRP CCL2 APOE APOB APOA1
6 cerebrovascular disease 32.4 VCAM1 TLR4 PON1 INS CRP APOE
7 familial lcat deficiency 32.3 APOE APOA1
8 tangier disease 32.3 APOE APOB APOA1 ABCA1
9 homocysteinemia 32.3 VCAM1 PON1 H19 CRP CCL2 APOE
10 familial hypercholesterolemia 32.3 VCAM1 PON1 INS CRP APOE APOB
11 sitosterolemia 32.3 APOB APOA1 ABCA1
12 chlamydia 32.1 TLR4 CRP CCL2
13 myocardial infarction 32.1 VCAM1 TLR4 PON1 INS CRP CDKN2B-AS1
14 hyperlipoproteinemia, type iii 32.1 APOE APOB APOA1
15 chlamydia pneumonia 32.1 TLR4 CRP CCL2 APOE
16 hypercholesterolemia, familial, 2 32.0 APOE APOB
17 hyperlipoproteinemia, type iv 32.0 APOE APOB APOA1
18 angina pectoris 31.9 INS CRP APOA1
19 heart disease 31.8 VCAM1 TLR4 PON1 INS H19 CRP
20 peripheral artery disease 31.8 VCAM1 CRP CDKN2B-AS1 CCL2 APOE APOB
21 kidney disease 31.8 VCAM1 PON1 INS CRP CCL2 APOE
22 diabetes mellitus 31.8 VCAM1 TUG1 TLR4 PON1 INS CRP
23 intermediate coronary syndrome 31.7 VCAM1 INS CRP APOB APOA1
24 stroke, ischemic 31.7 TLR4 PON1 CRP CDKN2B-AS1 APOE APOB
25 chronic kidney disease 31.7 VCAM1 TUG1 TLR4 PON1 INS CRP
26 end stage renal disease 31.7 PON1 INS CRP CCL2 APOB
27 sleep apnea 31.6 VCAM1 INS CRP CCL2 APOE APOB
28 aortic aneurysm, familial abdominal, 1 31.5 VCAM1 H19 CRP CDKN2B-AS1 CCL2 APOE
29 antiphospholipid syndrome 31.5 VCAM1 PON1 CRP
30 uremia 31.4 PON1 INS CRP
31 hypothyroidism 31.4 PON1 INS CRP APOB APOA1
32 body mass index quantitative trait locus 11 31.4 VCAM1 TLR4 PON1 INS H19 CRP
33 cardiovascular system disease 31.4 VCAM1 TLR4 PON1 INS CRP CDKN2B-AS1
34 lipid metabolism disorder 31.4 PON1 INS CRP CCL2 APOE APOB
35 hypertension, essential 31.4 VCAM1 TLR4 PON1 INS CRP CDKN2B-AS1
36 homozygous familial hypercholesterolemia 31.3 APOE APOB APOA1 ABCA1
37 acute myocardial infarction 31.3 CRP CDKN2B-AS1 APOB APOA1
38 non-alcoholic steatohepatitis 31.3 TLR4 INS CCL2 APOE
39 pulmonary disease, chronic obstructive 31.3 TUG1 INS CRP CCL2
40 type 1 diabetes mellitus 31.3 TLR4 PON1 INS CRP CCL2 APOB
41 hyperlipidemia, familial combined, 3 31.3 PON1 INS APOE APOB APOA1
42 xanthomatosis 31.3 APOE APOB ABCA1
43 lipid storage disease 31.2 TLR4 INS CRP CCL2 APOB
44 acute insulin response 31.2 INS CRP
45 macular degeneration, age-related, 1 31.2 INS CRP CCL2 APOE APOB ABCA1
46 familial hyperlipidemia 31.1 PON1 INS CRP APOE APOB APOA1
47 lipoprotein quantitative trait locus 31.1 VCAM1 PON1 INS H19 CRP CDKN2B-AS1
48 apnea, obstructive sleep 31.1 INS CRP APOE
49 vascular dementia 31.1 PON1 CRP APOE
50 alzheimer disease 31.1 PON1 INS CDKN2B-AS1 APOE APOA1 ALOX5

Graphical network of the top 20 diseases related to Atherosclerosis Susceptibility:



Diseases related to Atherosclerosis Susceptibility

Symptoms & Phenotypes for Atherosclerosis Susceptibility

Human phenotypes related to Atherosclerosis Susceptibility:

31
# Description HPO Frequency HPO Source Accession
1 hypertriglyceridemia 31 HP:0002155
2 myocardial infarction 31 HP:0001658
3 decreased hdl cholesterol concentration 31 HP:0003233

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Cardiac:
increased myocardial infarction risk

Lab:
preponderance of small, dense low density lipoprotein (ldl) particles (subclass pattern b)
increased triglyceride-rich lipoproteins
reduced high density lipoprotein

Clinical features from OMIM®:

108725 (Updated 05-Apr-2021)

UMLS symptoms related to Atherosclerosis Susceptibility:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Atherosclerosis Susceptibility according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.32 ABCA1

Drugs & Therapeutics for Atherosclerosis Susceptibility

PubMed Health treatment related to Atherosclerosis Susceptibility: 62

Treatments for atherosclerosis may include lifestyle changes, medicines, and medical procedures or surgery . The goals of treatment include: Relieving symptoms Reducing risk factors in an effort to slow or stop the buildup of plaque Lowering the risk of blood clots forming Widening or bypassing plaque -clogged arteries Preventing atherosclerosis -related diseases

Drugs for Atherosclerosis Susceptibility (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 551)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Rimonabant Approved, Investigational Phase 4 168273-06-1, 158681-13-1 104850
4
Enalaprilat Approved Phase 4 76420-72-9 6917719
5
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Warfarin Approved Phase 4 81-81-2 54678486 6691
8
Nitric Oxide Approved Phase 4 10102-43-9 145068
9
Dipyridamole Approved Phase 4 58-32-2 3108
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Caffeine Approved Phase 4 58-08-2 2519
12
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
13
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
14
Molsidomine Approved, Investigational Phase 4 25717-80-0
15
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
16
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
17
Zinc Approved, Investigational Phase 4 7440-66-6 32051
18
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
19
Ticlopidine Approved Phase 4 55142-85-3 5472
20
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
21
Propranolol Approved, Investigational Phase 4 525-66-6 4946
22
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
23
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
24
Insulin detemir Approved Phase 4 169148-63-4 5311023
25
Remifentanil Approved Phase 4 132875-61-7 60815
26
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
27
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
28
Saxagliptin Approved Phase 4 361442-04-8 11243969
29
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
30
Pravastatin Approved Phase 4 81093-37-0 54687
31
Acetaminophen Approved Phase 4 103-90-2 1983
32
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
33
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
34
Calcium acetate Approved, Investigational Phase 4 62-54-4
35
Testosterone Approved, Investigational Phase 4 58-22-0 6013
36
Methyltestosterone Approved Phase 4 58-18-4 6010
37
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
38
Testosterone enanthate Approved Phase 4 315-37-7 9416
39
Glimepiride Approved Phase 4 93479-97-1 3476
40
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
41
Bisoprolol Approved Phase 4 66722-44-9 2405
42
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
43
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
44
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
45
Racepinephrine Approved Phase 4 329-65-7 838
46
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
47
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
48
Anthralin Approved Phase 4 1143-38-0
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 1568)
# Name Status NCT ID Phase Drugs
1 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
2 Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound Unknown status NCT00155350 Phase 4 pioglitazone
3 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
6 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
7 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
8 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
9 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
10 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
11 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
12 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
13 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
14 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
15 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
16 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4 vitamin A;placebo
17 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
18 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
19 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
20 The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients Unknown status NCT00470808 Phase 4 POMx
21 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
22 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On Unknown status NCT03597035 Phase 4 Spironolactone
23 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
24 Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis Unknown status NCT00640744 Phase 4 Atorvastatin
25 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
26 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
27 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
28 Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM Unknown status NCT02162550 Phase 4 Bydureon;placebo
29 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
30 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
31 A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
32 Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study Unknown status NCT00484965 Phase 4
33 Chinese PLA General Hospital Hainan Branch Unknown status NCT03602638 Phase 4 Sitagliptin;Acarbose
34 Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab - a Pilot Study Unknown status NCT02992301 Phase 4 Alirocumab
35 The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults Unknown status NCT00750789 Phase 4
36 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
37 Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4 Atorvastatin
38 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
39 The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients Unknown status NCT01414972 Phase 4 Vitamin A;placebo
40 Pilot Prospective Study of Two Methods of Revascularization of the Superficial Femoral Artery: Stenting in the Superficial Femoral Artery, and Stenting of the Superficial Femoral Artery, Supplemented by Fasciotomy in Hunter Channel in Patients With Steno-occlusive Lesions of Femoral-popliteal Segment TASC C, D Unknown status NCT02590471 Phase 4
41 A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
42 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
43 Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy Unknown status NCT00715273 Phase 4 Atorvastatin;Niacin;Colesevelam;Placebo Niacin;Placebo Colesevelam
44 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
45 A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease Completed NCT00471341 Phase 4 Celecoxib;placebo
46 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
47 Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study Completed NCT00400543 Phase 4
48 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed NCT02376010 Phase 4 rivaroxaban;Warfarin
49 Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? Completed NCT00457405 Phase 4 dipyridamole
50 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo

Search NIH Clinical Center for Atherosclerosis Susceptibility

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: atherosclerosis

Genetic Tests for Atherosclerosis Susceptibility

Genetic tests related to Atherosclerosis Susceptibility:

# Genetic test Affiliating Genes
1 Atherosclerosis 29

Anatomical Context for Atherosclerosis Susceptibility

MalaCards organs/tissues related to Atherosclerosis Susceptibility:

40
Endothelial, Heart, Liver, Smooth Muscle, Kidney, Bone, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Atherosclerosis Susceptibility:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Coronary Capillary Plexus Affected by disease
2 Heart Coronary Vessels Affected by disease
3 Endothelium Arteries Arterial Endothelial Cells Affected by disease

Publications for Atherosclerosis Susceptibility

Articles related to Atherosclerosis Susceptibility:

(show top 50) (show all 33317)
# Title Authors PMID Year
1
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. 54 61 6
14702425 2004
2
Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. 61 54 57
1731344 1992
3
Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. 57 61
20421368 2010
4
Multilocus genetic determinants of LDL particle size in coronary artery disease families. 57 54
8644718 1996
5
The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis. 42 61
33578549 2021
6
Regulatory effect of traditional Chinese medicine on gut microbiota in patients with atherosclerosis: A protocol for systematic review and meta-analysis. 42 61
33327364 2020
7
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 6
10369259 1999
8
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. 57
9683593 1998
9
Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. 57
9683614 1998
10
The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene. 57
9184244 1997
11
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 6
9062372 1997
12
Low-density lipoprotein subclass patterns and risk of myocardial infarction. 57
3418853 1988
13
Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation therapy in treating with atherosclerotic cardiovascular disease: A protocol for systematic review and meta-analysis. 42
33350725 2020
14
Extracellular phospholipases in atherosclerosis. 54 61
20153800 2010
15
Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. 61 54
19687018 2010
16
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. 61 54
20395699 2010
17
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. 61 54
20360257 2010
18
Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. 54 61
20182519 2010
19
Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. 54 61
20167662 2010
20
Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. 61 54
20134100 2010
21
Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. 61 54
20444418 2010
22
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. 54 61
20154064 2010
23
Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study. 54 61
20187767 2010
24
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. 61 54
20439543 2010
25
MMP2 genetic variation is associated with measures of fibrous cap thickness: The Atherosclerosis Risk in Communities Carotid MRI Study. 54 61
20064641 2010
26
Soluble epoxide hydrolase in atherosclerosis. 54 61
20425256 2010
27
Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. The Cardiovascular Risk in Young Finns Study. 54 61
20350254 2010
28
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. 61 54
20370486 2010
29
Toll like receptor 4 in atherosclerosis and plaque destabilization. 61 54
19900676 2010
30
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. 54 61
19896127 2010
31
Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. 54 61
19931584 2010
32
[Association of the ALOX5AP gene SG13S114 A/T polymorphism with atherosclerosis]. 61 54
20376802 2010
33
Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. 61 54
20064818 2010
34
Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. 61 54
19845792 2010
35
Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. 61 54
19766217 2010
36
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. 54 61
20110287 2010
37
Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? 61 54
20197564 2010
38
Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression. 54 61
19230958 2010
39
Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. 54 61
19834878 2010
40
Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. 61 54
20142250 2010
41
[LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis]. 61 54
20146162 2010
42
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 61 54
20078196 2010
43
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages. 54 61
20137092 2010
44
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. 61 54
20145358 2010
45
Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. 54 61
20124121 2010
46
[Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice]. 54 61
20158089 2010
47
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 54 61
20158099 2010
48
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 54 61
19910639 2010
49
Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. 54 61
19909825 2010
50
A role for MMP-3 genetic variation in atherosclerosis susceptibility? 61 54
19815209 2010